文献速递骨质疏松与代谢性骨病

阿仑膦酸钠可维持镰状细胞病合并骨质疏松成人的骨密度

Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis.
PubMed 文献 · Osteoporos Int · 2024-10-22

本研究回顾性分析巴西单中心2009至2019年64例镰状细胞病合并骨质疏松成人使用阿仑膦酸钠的数据,中位治疗48个月。腰椎骨密度在治疗超过5年者中平均变化0.0357 g/cm2(p=0.028),性別与骨密度变化无显著交互作用,副作用多为轻度自限,但1例37岁男性治疗4年后出现非典型股骨骨干骨折。

要点

  • 镰状细胞病合并骨质疏松成人使用阿仑膦酸钠中位48个月,腰椎骨密度在治疗超过5年者中平均变化0.0357 g/cm2(p=0.028)。
  • 女性基线股骨颈和全髋骨密度显著低于男性,但两性间骨密度变化无显著差异。
  • 4例(6.3%)报告轻度治疗相关副作用,1例37岁男性治疗4年后偶然发现非典型股骨骨干骨折。

核心结论

  • 在64例使用阿仑膦酸钠中位48个月的镰状细胞病合并骨质疏松成人回顾性队列中,性别与腰椎、股骨颈或全髋骨密度变化之间无显著交互作用。
  • 治疗不足5年者腰椎骨密度保持稳定;副作用多为轻度,但1例患者出现非典型股骨骨折。

研究设计与样本

  • 回顾性临床数据分析,纳入巴西单中心2009至2019年接受阿仑膦酸钠治疗的镰状细胞病合并骨质疏松成人64例。
  • 通过双能X线吸收法测量腰椎、股骨颈和全髋骨密度,按治疗时长(月)、性别、骨骼部位和镰状细胞病基因型分层分析骨密度变化。

主要发现

  • 64例中女性占69%,HbSS基因型占73%,平均年龄42.4±10.9岁,阿仑膦酸钠治疗中位(四分位距)48(29,73)个月。
  • 女性基线股骨颈骨密度0.72 vs 男性0.85 g/cm2(p<0.001),全髋骨密度0.79 vs 0.88 g/cm2(p=0.009),女性显著低于男性。
  • 两性间骨密度变化差异不显著。
  • 治疗超过5年者腰椎骨密度平均显著变化0.0357 g/cm2(p=0.028)。
  • 4例(6.3%)报告轻度治疗相关副作用;1例37岁男性治疗4年后偶然发现归因于阿仑膦酸钠的非典型股骨骨干骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Low bone mineral density is highly prevalent in sickle cell disease (SCD); whether bisphosphonates can safely preserve or increase bone mass in SCD adults remains unknown. In this study, lumbar spine bone density remained stable with alendronate use, and treatment-related side effects were mostly mild and self-limited. PURPOSE: To describe the effects of alendronate in adults with sickle cell disease (SCD) and osteoporosis. METHODS: We reviewed retrospective clinical data from adults with SCD and osteoporosis treated with alendronate at a single center in Brazil (2009-2019). Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA) of the lumbar spine, femoral neck, and total hip. We analyzed BMD changes by alendronate treatment duration (months), stratified by sex, skeletal site, and SCD genotype. RESULTS: Sixty-four SCD adults with osteoporosis (69% females, 73% HbSS, mean age ± standard deviation 42.4 ± 10.9 years) received alendronate for a median (interquartile range) of 48 (29, 73) months. Compared with males, females had significantly lower baseline BMD (g/cm2) at the femoral neck (0.72 vs 0.85, p = < 0.001) and total hip (0.79 vs 0.88, p = 0.009). The between-sex differences in BMD changes were insignificant. Mean lumbar spine BMD significantly changed by 0.0357 g/cm2 (p = 0.028) in those on alendronate for > 5 years. Four adults (6.3%) reported mild therapy-related side effects. An atypical femoral diaphysis fracture, attributed to alendronate, was incidentally noted in a 37-year-old man on treatment for 4 years. CONCLUSION: In this retrospective cohort of adults with SCD and osteoporosis on alendronate for a median of 48 months, we found no significant interactions between sex and changes in lumbar spine, femoral neck, or total hip BMD with alendronate. Lumbar spine BMD was stable in those on alendronate for < 5 years. Side effects of alendronate were mild, though one patient developed an atypical femoral fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Adesina OO, Jenkins IC, Galvão F, et al. Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis. Osteoporos Int. 2024. PMID: 39433652. doi:10.1007/s00198-024-07268-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。